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Abstract
Background: In critically ill patients, poor patient-ventilator interaction may worsen outcomes. Although sedatives
are often administered to improve comfort and facilitate ventilation, they can be deleterious. Whether opioids
improve asynchronies with fewer negative effects is unknown. We hypothesized that opioids alone would improve
asynchronies and result in more wakeful patients than sedatives alone or sedatives-plus-opioids.
Methods: This prospective multicenter observational trial enrolled critically ill adults mechanically ventilated
(MV) > 24 h. We compared asynchronies and sedation depth in patients receiving sedatives, opioids, or both.
We recorded sedation level and doses of sedatives and opioids. BetterCare™ software continuously registered
ineffective inspiratory efforts during expiration (IEE), double cycling (DC), and asynchrony index (AI) as well as
MV modes. All variables were averaged per day. We used linear mixed-effects models to analyze the relationships
between asynchronies, sedation level, and sedative and opioid doses.
Results: In 79 patients, 14,166,469 breaths were recorded during 579 days of MV. Overall asynchronies were
not significantly different in days classified as sedatives-only, opioids-only, and sedatives-plus-opioids and were
more prevalent in days classified as no-drugs than in those classified as sedatives-plus-opioids, irrespective of
the ventilatory mode. Sedative doses were associated with sedation level and with reduced DC (p < 0.0001) in
sedatives-only days. However, on days classified as sedatives-plus-opioids, higher sedative doses and deeper
sedation had more IEE (p < 0.0001) and higher AI (p = 0.0004). Opioid dosing was inversely associated with
overall asynchronies (p < 0.001) without worsening sedation levels into morbid ranges.
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Conclusions: Sedatives, whether alone or combined with opioids, do not result in better patient-ventilator
interaction than opioids alone, in any ventilatory mode. Higher opioid dose (alone or with sedatives) was
associated with lower AI without depressing consciousness. Higher sedative doses administered alone were
associated only with less DC.
Trial registration: ClinicalTrial.gov, NCT03451461
Keywords: Asynchronies, Mechanical ventilation, Sedatives, Opioids, Double cycling, Ineffective inspiratory
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Background
Patient-ventilator asynchronies are frequent during inva-
sive mechanical ventilation (MV) [1, 2]. Poor patient-
ventilator interaction could be associated with prolonga-
tion of MV, longer intensive care unit (ICU) and hospital
stays [2], and increased mortality [1, 3]. Thus, optimizing
patient-ventilator interaction may improve outcomes [4].
Many aspects of clinical management affect patient-
ventilator interaction. Adjusting ventilator settings can
decrease asynchronies and associated anxiety and dys-
pnea [5, 6]. Sedatives can cause ventilatory depression
affecting respiratory drive and timing, worsening
patient-ventilator interaction in proportion to decreasing
level of consciousness [7, 8]; these effects appear to dif-
fer with different drugs [9, 10]. Sedation is associated
with deleterious side effects. Deep sedation is associated
with worse short- and long-term outcomes [11–14]. For-
going or minimizing sedatives during MV is increasingly
recommended [15–17].
The relationship between asynchronies, level of con-
sciousness (sedation level), and sedatives and opioids is
poorly understood. Increasing sedatives in ICU patients
with double cycling (DC) not only failed to correct this
asynchrony [6], but also prolonged MV and ICU and
hospital stays. The rate of ineffective inspiratory efforts
increases proportionately with the depth of sedation [8].
Different studies have reported disparate effects of seda-
tive dosage on the overall rate of asynchronies. Whereas
one study found that light sedation with propofol did
not affect the rate of asynchronies but deep sedation
with propofol increased it [10], another found that deep
sedation reduced but did not eliminate asynchronies
[18]. A recent study showed that deep sedation, benzodi-
azepines, and cumulative doses of benzodiazepines were
associated with higher mortality [19]. In another trial,
patients on dexmedetomidine had slightly fewer asyn-
chronies than those on propofol [20]. However, these
studies did not take opioid administration into account.
Opioids are commonly used in ICU patients. In a
study comparing midazolam vs. fentanyl plus midazo-
lam, patients receiving fentanyl had fewer asynchronies
than those receiving only midazolam [21]. Thus, the
effects of opioids alone or together with sedatives on
asynchronies warrant investigation. Adequate opioid
treatment with minimal doses of sedatives might enable
more spontaneous breathing and improve patient-
ventilator interaction; however, the relationships be-
tween opioids, level of consciousness, and asynchronies
remain to be elucidated. We hypothesized that opioids
alone would improve trigger and cycling asynchronies
and result in more wakeful patients than sedatives alone
or sedatives-plus-opioids.
Methods
Study population and design
We obtained data from an ongoing database started in
2011 in four centers in Spain. The database was con-
structed prospectively with funding for a project to de-
velop a connectivity platform to interoperate signals from
different ventilators and monitors and subsequently
compute algorithms to diagnose patient-ventilator asyn-
chronies (ClinicalTrial.gov, NCT03451461); each institu-
tion’s review board approved the database.
This prospective observational study included adult
patients admitted to four ICUs between October 2011
and January 2013. The institutional review boards ap-
proved the protocol, waiving informed consent because
the study was non-interventional, posed no added risk
to patients, and did not interfere with usual care.
Patients were prospectively included when the follow-
ing criteria were met: admission to a bed equipped with
BetterCare™ software and intubated for MV expected to
last > 24 h. To avoid selection bias, members of the re-
search team were not involved in assigning patients to a
bed equipped with BetterCare™ software. Exclusion cri-
teria were < 48 h of data, age < 18 years, pregnancy, do-
not-resuscitate orders, admission for organ donation,
and chest tubes with suspected bronchopleural fistula.
Patient management and data collection
Demographic and clinical data were obtained from med-
ical records. Level of consciousness was assessed every 4
h with the Riker Sedation-Agitation Scale (SAS), and the
mean value of these assessments was computed to
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obtain a daily average. Illness severity was assessed daily
with the Sequential Organ Failure Assessment (SOFA).
ICU teams were aware of the recording system, but not
of the study hypothesis. All patients were managed with
similar processes of care and lung-protective ventilation
strategies (tidal volume 6mL/kg ideal body weight and
plateau pressure under 30 cmH2O) following the quality
indicators of the Spanish Society of Intensive Care Medi-
cine (https://semicyuc.org/wp-content/uploads/2018/10/
quality_indicators_update_2011.pdf ) throughout the
study. Patients were ventilated with Evita 4 (Dräger,
Lübeck, Germany), Puritan Bennet 840 (Covidien,
Plymouth, MN, USA), or Servo I (Maquet, Fairfield, NJ,
Sweden) ventilators, receiving volume assist/control,
pressure assist control, or pressure support based on cli-
nicians’ assessment of clinical status. Ventilatory modes
were analyzed as previously described [22]. The predom-
inant mode for each day analyzed was classified as
assist-control or pressure-support if the patient
remained in that mode for ≥ 70% of the time. Other
ventilator parameters were also adjusted at the discre-
tion of the attending physician following national recom-
mendations. Clinicians adjusted ventilator settings when
asynchronies were observed at the bedside, but adjust-
ments were not protocolized.
Total doses of opioids (morphine and fentanyl) and
sedatives (midazolam, propofol, and lorazepam) admin-
istered each day were recorded and converted to mor-
phine and midazolam equivalents [6]. We classified each
day of MV for a given patient as (1) no-drugs, (2)
sedatives-only, (3) opioids-only, or (4) sedatives-plus-
opioids. To avoid misleading classifications due to re-
sidual treatment effects, days were classified according
to all medications administered during the day; thus, a
day in which a patient received sedatives-plus-opioids
for > 2 h and opioids-only thereafter would be classified
as “sedatives-plus-opioids.” Days in which patients were
treated with neuromuscular blockers were excluded
from the analysis. Sedatives and analgesia were managed
following each ICU’s protocols based on the Spanish So-
ciety of Intensive Care Medicine recommendations [23],
SAS level, and pain and discomfort assessments.
For the analyses, data was structured as averaged mea-
sures per day. Therefore, every treatment group could
include a different number of patients depending on the
day.
Analysis of asynchronies
Asynchronies were detected by BetterCare™ software
(Barcelona, Spain), which continuously records airflow,
airway pressure, and tidal volume from admission to
extubation or death. BetterCare™ identifies the begin-
nings of inspiration and expiration to analyze and store
data breath by breath. It analyzes each breath to detect
four types of asynchronies (ineffective inspiratory efforts
during expiration (IEE), DC, short cycling/aborted in-
spiration, and prolonged cycling [1, 2]) and computes
the asynchrony index (AI) (Additional file 1) [24]. Pe-
riods in which recording was interrupted due to clinical
interventions, out-of-ICU transfers, technical problems,
or other issues were excluded from the analysis, which
was done on the remaining valid periods.
All asynchronies were averaged per day. The rates of
IEE, DC, and the overall AI were computed considering
the total number of breaths (ventilator-delivered cycles
plus IEE), enabling us to compare days, despite varying
respiratory rates.
Statistical analysis
Patients’ characteristics are summarized as medians (25th–
75th percentiles) or percentages. Sample size calculation
was considered unnecessary for this exploratory study.
To analyze the level of consciousness and illness sever-
ity by treatment groups, we used linear mixed-effects
(LME) models with random intercepts for the patients.
This approach takes inter- and intra-subject variability
in longitudinal data into account; each patient differs
from the overall mean response by an individual-specific
constant that applies equally over time [25]. To analyze
asynchronies by treatment groups, we used generalized
LME (GLME) models assuming a negative binomial dis-
tribution for the response variable (number of asyn-
chrony events) because the variable response was
discrete, limited to non-negative values, and positively
skewed with most observations having values near zero.
Negative binomial distributions are often used in regres-
sion models with count data. Furthermore, to analyze
the number of asynchrony events as a rate, we incorpo-
rated an exposure term (total number of respiratory cy-
cles per day) that indicates the number of times a
particular event occurred.
To assess the effects of level of consciousness and se-
verity of illness on each type of asynchrony, we also used
GLME models with random intercepts for the patients
and allowing variation in SAS and SOFA slopes by treat-
ment groups for the population mean.
To explore the effects of dosage on level of conscious-
ness and asynchronies, we used a LME model and GLME
models, respectively. This analysis included the opioids-
only, sedatives-only, and sedatives-plus-opioids groups.
These models used random intercepts only for the pa-
tients and allowed variations in slopes for dose equivalents
by treatment groups for the population mean. Addition-
ally, we investigated the effect of severity (SOFA) as a po-
tential confounding variable that could influence both the
asynchronies and the treatment group.
We used R 3.3.1 (R Core Team, Vienna, Austria, URL
http://www.R-project.org) for all analyses, building the
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mixed-effects models with the lme4 package [25] and
summarizing the mean (95% CI) effects by treatment
groups with the lsmeans package. When using LME
models for the continuous response variables, we
checked the normality assumptions for the estimated
random effects and for the within-subject residuals by
graphical methods (normal Q-Q plots). When the re-
sponse variable was discrete, we assessed overdispersion
by graphical comparison of the standardized residuals
versus the fitted values. Significance was set at p < 0.01.
Pairwise comparisons among treatment groups were
two-sided and adjusted by the Bonferroni method to
maintain the significance level.
Results
Table 1 reports on the demographic, clinical, and out-
come data for the 79 patients. We analyzed 579 days on
invasive MV, comprising 14,166,469 breaths.
Relationship between asynchronies and treatment group
Figure 1 shows the relationship between each asyn-
chrony and treatment group. No statistically significant
differences in AI, IEE, or DC were found between
sedatives-only, opioids-only, and sedatives-plus-opioids
days. The AI and rates of IEE and DC were higher for
no-drugs days than for sedatives-plus-opioids days; AI
was also higher for no-drugs than for opioids-only days.
Relationships between treatment group, level of
consciousness, and severity of illness
Mean daily SAS in sedatives-plus-opioids days [2.4
(95%CI 2.2–2.6)] was lower than in opioids-only [3.1
(95%CI 2.8–3.4); p < 0.0001], sedatives-only [2.9 (95%CI
2.6–3.2); p = 0.002], and no-drugs days [3.3 (95%CI 3.1–
3.6); p < 0.0001]. Mean daily SAS in no-drugs days was
higher than in sedatives-only days (p = 0.006) (Fig. 2).
SOFA scores in sedatives-plus-opioids days were higher
than in no-drugs (p < 0.0001), sedatives-only (p = 0.004),
and opioids-only days (p = 0.008); SOFA scores were
similar in the no-drugs, sedatives-only, and opioids-only
groups (Fig. 2).
Table 2 summarizes the relationships of the level of
consciousness and severity with asynchronies in the
treatment groups. Higher level of consciousness was
associated with higher DC rates (p < 0.0001) in
sedatives-plus-opioids and sedatives-only days (p <
0.0001). However, the level of consciousness was not
associated with AI or IEE regardless of exposure to
opioids or sedatives. SOFA was not associated with
AI or IEE, but was associated with a higher DC rate
in no-drugs days (p = 0.008).
Relationship between asynchronies and drug doses
Figure 3 illustrates the relationship between each asyn-
chrony and doses of sedatives (left) and opioids (right).
In opioids-only days (red, right panel, Fig. 3), the opioid
dose was inversely associated with AI (p < 0.001), IEE
(p = 0.0002), and DC (p < 0.0001). In sedatives-plus-
opioids days (blue, right panel, Fig. 3), opioid dose was
also inversely associated with AI, IEE, and DC (p <
0.0001), whereas sedative dose was directly associated
with AI (p = 0.0004) and IEE (p < 0.0001), but not with
DC (in blue, left panel Fig. 3). However, in sedatives-
only days (red trace, left panel Fig. 3), sedative doses
were inversely associated only with DC (p < 0.0001).
Additional file 2: Table S1 reports on the regression co-
efficients and performance of the model examining the
relationship between medication dose and asynchronies.
When SOFA score was included as a potential con-
founding factor (Additional file 2: Table S2), the direc-
tion of the above statistically significant associations
remained unchanged, except in the opioids-only for the
DC model, where the association was no longer signifi-
cant. In addition, the SOFA was not associated with any
of the asynchrony variables.
Table 1 Patients’ demographic and clinical characteristics
Total population (n = 79) Median [25th,
75th percentiles]
Percentage
Age (years) 63 [52, 75]
Sex (% men) 64.5%
Reason for admission n
Acute respiratory failure 39 (49.4%)
- Sepsis 12 (15.2%)
- Pneumonia 7 (8.7%)
- ARDS 5 (6.3%)
- COPD 3 (3.8%)
- Congestive heart failure 2 (2.5%)
- Other 10 (12.7%)
Neurologic 15 (19%)
Cardiac arrest 10 (12.7%)
Postsurgical 8 (10.1%)
Multiple trauma 6 (7.6%)
Neuromuscular disease 1 (1.3%)
APACHE II 17 [10, 26]
SOFA at admission 7 [5.25, 10.75]
Length of mechanical ventilation (days) 6 [3, 10.5]
ICU stay (days) 10 [6, 18]
Hospital stay (days) 23 [11, 50]
Mortality ICU 27.9%
ARDS acute respiratory distress syndrome, COPD chronic obstructive
pulmonary disease, APACHE Acute Physiology and Chronic Health Evaluation,
SOFA Sequential Organ Failure Assessment score, ICU intensive care unit
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Relationship between drug dose and level of
consciousness
Additional file 3: Figure S2 shows the relationship be-
tween the level of consciousness and doses of sedatives
(left panel) and of opioids (right panel). Higher sedative
doses were associated with a lower level of conscious-
ness, in both sedatives-only (p < 0.0001; red, left panel)
and sedatives-plus-opioids days (p = 0.004; blue, left
panel). Opioid doses were not associated with the level
of consciousness.
Relationship between asynchronies, treatment group, and
mechanical ventilation modes
We analyzed the effect of MV modes in the incidence of
asynchronies in each treatment group. There were no
statistically significant differences in the AI, IEE, or DC
Fig. 1 Mean percentages of asynchronous breaths estimated with the generalized linear mixed-effects model by treatment groups. Data are
represented as mean (95% CI). Statistical significance (two-sided) among groups is indicated; p values are adjusted by the Bonferroni method
Fig. 2 Mean levels of SAS and SOFA estimated with the linear mixed-effects model by treatment groups. Data are represented as mean (95% CI).
Statistical significance (two-sided) among groups is indicated; p values are adjusted by the Bonferroni method. The within-subject residuals of the
SOFA model departure from the theoretical normal distribution (see Additional file 5: Figure S4 left)
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between assist-control and pressure support modes in
any treatment group (p > 0.01). In assist-control mode,
the opioids-only and sedatives-plus-opioids groups had a
lower AI than the no-drugs group (p = 0.0065 and p =
0.0028, respectively) (Fig. 4) (Additional file 4: Table S3).
Discussion
This is the first study to present data relating asyn-
chronies and treatment with sedatives and opioids
throughout the complete MV period. The overall rate of
asynchronies did not differ between days classified as
opioids-only, sedatives-only, and sedatives-plus-opioids.
Patients receiving sedatives had a lower level of con-
sciousness than those receiving opioids-only; sedatives-
plus-opioids decreased the level of consciousness, but
did not result in fewer asynchronies than the other treat-
ments. Interestingly, in sedatives-plus-opioids days, the
sedative dose was directly associated with the rate of
asynchronies and with a lower level of consciousness,
whereas higher opioid doses were associated with a
lower AI without worsening level of consciousness.
Thus, opioid administration seems a clinically sound ap-
proach to improve patient-ventilator synchrony while
preserving consciousness.
Patients with shock or severe respiratory failure often
require sedatives. Moreover, sedatives are sometimes ad-
ministered in attempts to improve patient-ventilator inter-
action. However, deep sedation has been associated with
worse outcomes [13]. Lighter or no-sedation is favored in
partial ventilatory support modes, where patient-ventilator
synchrony is crucial. Physiological studies show that
sedatives have varying effects on asynchronies. In-
creasing sedatives/analgesia is relatively ineffective in
abolishing severe breath-stacking [6]. Deep sedation
with propofol increases asynchronies during pressure
support ventilation, whereas light sedation does not
[10]; deeper sedation is associated with increased inef-
fective triggering events [8] and with increased mor-
tality [26]. Thus, sedative management in MV is a
modifiable variable that could improve outcomes [26].
Associations between sedatives and asynchronies are
probably confounded by many factors, especially by cli-
nicians’ ventilator adjustments. In our study, the inci-
dence of asynchronies was associated with the drugs
used (sedatives and opioids), irrespective of the ventila-
tory mode. However, sedatives lowered patients’ level of
consciousness without decreasing asynchronies beyond
opioids alone. Inadequate pain control worsens patient-
ventilator synchrony [21] and is associated with agita-
tion, which negatively affects outcomes [27]. Richman
et al. [21] found that patients receiving midazolam-
plus-opioids had fewer asynchronies/day over a 3-day
period than those receiving midazolam alone. Our re-
sults support these findings, showing that opioids could
help improve asynchronies beyond sedatives, although
prospective trials are necessary to determine whether
appropriate opioids favor better synchrony by ensuring
adequate analgesia without depressing consciousness
and without affecting respiratory drive or minute venti-
lation [28–30].
Table 2 Mean estimated effect from the regression coefficient of SAS and SOFA on asynchronies, by treatment group
Treatment group Asynchrony Index Ineffective inspiratory efforts during expiration Double cycling
SAS
No drugs − 0.10 (− 0.29, 0.10)
p = 0.34
− 0.14 (− 0.36, 0.09)
p = 0.24
− 0.02 (− 0.25, 0.21)
p = 0.87
Sedatives 0.11 (− 0.09, 0.31)
p = 0.29
− 0.04 (− 0.27, 0.20)
p = 0.76
0.46 (0.23, 0.69)
p < 0.0001
Opioids − 0.17 (− 0.37, 0.04)
p = 0.12
− 0.20 (− 0.44, 0.04)
p = 0.10
0.08 (− 0.18, 0.33)
p = 0.55
Sedatives + opioids 0.14 (0.03, 0.26)
p = 0.17
0.12 (− 0.02, 0.26)
p = 0.09
0.30 (0.17, 0.44)
p < 0.0001
SOFA
No drugs 0.02 (− 0.03, 0.07)
p = 0.38
0.02 (− 0.04, 0.08)
p = 0.52
0.08 (0.02, 0.13)
p = 0.008
Sedatives 0.02 (− 0.05, 0.09)
p = 0.55
0.06 (− 0.02, 0.14)
p = 0.17
− 0.03 (− 0.12, 0.05)
p = 0.45
Opioids − 0.06 (− 0.13, 0.02)
p = 0.13
− 0.05 (− 0.13, 0.03)
p = 0.25
− 0.09 (− 0.17, − 0.01)
p = 0.03
Sedatives + opioids − 0.01 (− 0.05, 0.03)
p = 0.66
− 0.00 (− 0.05, 0.05)
p = 0.98
− 0.00 (− 0.05, 0.04)
p = 0.91
Results are expressed as mean estimated effect and 95% CI. A negative sign indicates an inverse association. Statistically significant associations are indicated
SAS Sedation Assessment Scale, SOFA Sequential Organ Failure Assessment
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Increasing sedative doses prolongs MV and ICU and
hospital stays [12, 14]. Paired with pain management pro-
tocols [17], sedation protocols including light sedation or
daily interruptions of sedation [13, 15, 16] improve ICU
patients’ outcomes. Our results suggest that, compared
with treatments including sedatives, treatment with
opioids-only enables patients to be more awake without
increasing asynchronies. Opioids-only treatment resulted
in a higher level of consciousness than treatment with
sedatives-plus-opioids. Our findings on the effects of seda-
tives and opioids throughout MV are in line with those of
a randomized clinical trial where MV patients receiving
morphine had more ventilator-free days and shorter ICU
stays than those receiving sedatives-plus-morphine, with-
out increases in accidental extubation or ventilator-
associated pneumonia [16]. Moreover, we found that in
assist-control modes, compared with no-drugs, treatment
with sedatives-plus-opioids and opioids-only favored bet-
ter patient-ventilation interaction (lower AI), suggesting
that opioids might improve patient comfort. Thus, it
might be beneficial to maintain opioid treatment until lib-
eration from MV.
Fig. 3 Effect of the dose of sedatives and opioids administered on asynchronies. Average change in asynchronies per one unit change in
dose equivalent
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We also found significantly lower AI, IEE, and DC in
sedatives-plus-opioids than in no-drugs days. However,
asynchronies in MV patients who do not require sedatives
or opioids probably are intrinsically different from those
that occur in patients who require these treatments, and
therefore, they probably require a different clinical ap-
proach. Rue et al. [31, 32] recently used a Bayesian joint
model incorporating longitudinal ICU stay markers to
evaluate outcome determinants. Finding that overall AI
was not associated with severity of illness or vital status,
they postulated that some asynchronies could be a marker
of life. In our study, we considered the effect of severity of
illness to better understand this possible confounding fac-
tor. We found no associations between severity and AI or
IEE (Table 2), so patients with more asynchronies were
not necessarily more severely ill. The lower severity and
higher rates of asynchronies in no-drugs days compared
with sedatives-only, opioids-only, and sedatives-plus-
opioids days are likely due to differences in the origin and
behavior of the asynchronies that occur in the different
groups. Therefore, from a clinical perspective, it makes no
sense to compare asynchronies and their management in
no-drugs versus in treatment days [3, 33].
Finally, our analysis of the relationship between asyn-
chronies and drug dosage found that, unlike sedatives, in-
creasing doses of opioids were associated with decreasing
rates of asynchronies, without significantly affecting the
level of consciousness, independently of the level of sever-
ity. This finding highlights the importance of titrating opi-
oids for comfort, and possibly asynchronies, in addition to
pain control.
Unlike some physiological studies, we found that seda-
tives, alone or together with opioids, did not decrease
asynchronies more than opioids-only. On the other
hand, our findings of increased rates of asynchronies, es-
pecially IEE, with an increased daily dose of sedatives
are in line with physiological studies [8, 10]. Whereas
physiological studies analyze only short time periods,
our study considered the entire period of MV, making it
closer to clinical practice. One strength of our study is
that it is based on prospectively accrued physiological
data with enough breadth and depth to characterize a
patient’s condition throughout MV. Observational trials
like this are increasingly being used because conclusions
drawn from data collected in real-world situations can
be more generalizable than the more restricted, if more
Fig. 4 Mean percentages of asynchronous breaths estimated with the generalized linear mixed-effects model according to mechanical ventilator
mode, by treatment groups. Data are represented as mean (95% CI)
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vigorous, conclusions of randomized clinical trials [34–
36]. Our findings add to the growing body of evidence
pointing to the inability of sedatives to prevent and/or
correct asynchronies in daily practice and the association
of opioids with improved asynchrony rates, thus sup-
porting the strategy of managing pain while maintaining
the lightest sedation possible [17, 37].
Our study has several limitations. First, patients were
not randomized to each drug regimen. Furthermore, pa-
tients received opioids, sedatives, or no-drugs in any se-
quence or combination as deemed clinically necessary.
Granular data for sedative or opioid doses over smaller
time intervals were unavailable, thus precluding analyses
of temporal associations between sedatives/opioids and
asynchronies that might have enabled causal inferences
and greater insight. Moreover, we did not consider fac-
tors that influenced clinicians to modify sedative or opi-
oid dosing. Patients often receive more drugs early in
MV and less when approaching weaning; however, to
counterbalance this bias, we explored the relationship
between severity and drugs and asynchronies, but found
no relevant associations. Additionally, we did not analyze
other painkillers such as acetaminophen and nonsteroi-
dal anti-inflammatory drugs, which may influence
patient-ventilator interaction differently, so our findings
cannot be extrapolated to other non-opioid drugs. We
used no objective measures of pain levels, precluding the
analysis of associations between pain and asynchronies.
Likewise, we did not measure surrogates of respiratory
center activity, so we cannot evaluate associations be-
tween respiratory drive and different asynchronies. As
individual patients could be considered in more than
one group because management strategies evolved from
day-to-day, our analysis of drug doses could not take
into account the prolonged half-life and accumulation of
some sedatives [38]. Nevertheless, we found a good rela-
tionship between SAS score and the sedative treatment
group. We analyzed only IEE and DC because they are
the most relevant asynchronies; we did not analyze flow
asynchronies because they cannot be established from
ventilator airway pressure and flow scalars alone. Thus,
our findings cannot be extrapolated to these asyn-
chronies. Additionally, because the measure unit was
days rather than patients, it was difficult to analyze the
effect of the underlying disease on the results. In an at-
tempt to overcome this difficulty, we adjusted the results
by including SOFA score as a marker of severity, but we
found no effect of severity in the incidence of asyn-
chronies per group. Finally, clinically detected asyn-
chronies were treated according to each ICU’s protocols;
thus, differences between centers might have affected
the results. We performed an analysis to evaluate the in-
fluence of each center and we did not find significant
differences between centers.
Conclusions
Our findings suggest that sedatives, alone or together
with opioids, do not decrease asynchronies beyond what
can be achieved with opioids alone, independently of
MV mode. Optimal titration of opioids might improve
patient-ventilator interaction while avoiding the deleteri-
ous effects of sedatives.
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